MDMA, a stimulant drug used recreationally for its mood-enhancing effects, can cause cognitive dysfunction, emotional dysregulation, and life-threatening hyperthermia with prolonged misuse. Despite these dangers, research indicates MDMA may become a valuable therapeutic adjunct for treating psychiatric conditions including PTSD, alcohol dependence, depression, and anxiety, and may also benefit athletic populations. Existing studies are limited by small sample sizes, underscoring the need for further large-scale research to confirm these findings.
Ibogaine, an indole alkaloid from the Tabernanthe iboga plant, shows promise for reducing withdrawal and cravings in opioid, cocaine, and alcohol use disorders by modulating serotonin, dopamine, and glutamate systems. However, serious safety risks, especially cardiotoxicity with QT prolongation and potentially fatal arrhythmias, limit its use. Further large-scale randomized controlled trials are needed to better assess its efficacy and safety.